Infinitopes To Showcase Breakthroughs On Cancer Vaccine Development At SITC 2024: Insight Into A Double-Blind, Phase I/Iia Clinical Trial
Infinitopes' lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, off-the-shelf c ...
Infinitopes to Showcase Breakthroughs on Cancer Vaccine Development at SITC 2024: Insight into a double-blind, Phase I/I
Infinitopes' lead vaccine candidate ITOP1 is a novel, precision targeted, immunologically durable, "off-the-shelf" cancer vaccine, designed to save lives by preventing disease recurrence in first-line ...